Search results for "From ACP Diabetes Monthly"
Spotlight on gut microbiota in diabetes
Connections between diabetes and gut microbiota were the focus of the latest "Keeping tabs" report from ACP Diabetes Monthly.
https://gastroenterology.acponline.org/archives/2024/07/26/7.htm
26 Jul 2024
Spotlight on the gut microbiome
A Finnish study found that certain gut bacteria were more common in people who later developed type 2 diabetes, while an Israeli study identified a distinct microbial signature in adults with type 1 diabetes compared with healthy controls.
https://gastroenterology.acponline.org/archives/2022/02/25/8.htm
25 Feb 2022
Spotlight on liver health in diabetes
A review compared liver outcomes for most classes of diabetes drugs, while a retrospective study looked at glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors head to head. Another study offered a new score for metabolic dysfunction-associated steatotic liver disease.
https://gastroenterology.acponline.org/archives/2024/10/25/8.htm
25 Oct 2024
Weight loss through gastric bypass or diet improved insulin sensitivity in patients with type 2 diabetes
Results from this small study suggest that reducing adipose tissue volume, by whatever means, will improve blood glucose control in patients with type 2 diabetes, an accompanying editorial noted.
https://gastroenterology.acponline.org/archives/2020/09/25/7.htm
25 Sep 2020
Roux-en-Y gastric bypass associated with better long-term diabetes outcomes than sleeve gastrectomy
While both procedures were associated with high rates of type 2 diabetes remission, the rate of remission five years after surgery was about 10% higher in patients who had gastric bypass than in those who had sleeve gastrectomy.
https://gastroenterology.acponline.org/archives/2020/03/27/8.htm
27 Mar 2020
Diabetes remission after bariatric surgery may be more likely in younger patients with shorter disease duration
Long-term results from the Longitudinal Assessment of Bariatric Surgery suggested that diabetes remission is more likely after bariatric surgery performed soon after diagnosis, when diabetes medication burden is low and beta-cell function is preserved, study authors noted.
https://gastroenterology.acponline.org/archives/2020/12/18/8.htm
18 Dec 2020
Incretin-based drugs not associated with any increase in risk for pancreatic diseases
The findings may reassure prescribers of dipeptidyl peptidase-4 inhibitors that the drug class does not significantly increase the risk of adverse pancreatic outcomes compared with other second-line therapies, study authors said.
https://gastroenterology.acponline.org/archives/2018/11/27/7.htm
27 Nov 2018
DPP-4 inhibitors associated with risk of cholecystitis, meta-analysis finds
Patients with type 2 diabetes who were randomized to receive dipeptidyl peptidase-4 (DPP-4) inhibitors had higher rates of gallbladder disease than those who got placebo or nonincretin drugs, but no difference in risk of cholelithiasis or biliary diseases.
https://gastroenterology.acponline.org/archives/2022/07/22/6.htm
22 Jul 2022
Bariatric surgeries reduced hepatic steatosis in type 2 diabetes at one year
Patients who were randomized to either sleeve gastrectomy or Roux-en-Y gastric bypass showed similar improvements in hepatic steatosis and fibrosis, a randomized trial in Norway found.
https://gastroenterology.acponline.org/archives/2021/12/17/8.htm
17 Dec 2021
Severe insulin-resistant diabetes associated with better metabolic surgery outcomes
Patients with severe insulin-resistant diabetes had better outcomes after metabolic surgery than those with mild obesity-related diabetes or severe insulin-deficient diabetes, both in terms of type 2 diabetes remission and renal function, with no additional surgical risk.
https://gastroenterology.acponline.org/archives/2022/03/25/6.htm
25 Mar 2022